Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy

Annals of Internal Medicine

Volumn 131, Issue 10, 1999, Pages 768-774

  Pincus, Theodore ^a   O'Dell, James R ^b   Kremer, Joel M ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ARTHROPATHY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0032760136     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-10-199911160-00009     Document Type: Review

References (104)

1. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl. 1996;44:47-51.
2. Kantor TG. Order out of chaos - the primary mission of the pyramid [Editorial]. J Rheumatol. 1990;17:1580-1.
3. Lightfoot RW Jr. Treatment of rheumatoid arthritis. In: McCarty DJ, ed. Arthritis and Allied Conditions. Philadelphia: Lea & Febiger; 1985:668-76.
4. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol. 1989;16:565-7.
5. Pincus T, Callahan LF. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - lessons from Hodgkin's disease and coronary artery disease [Editorial]. J Rheumatol. 1990;17:1582-5.
6. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventyfive rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-72.
7. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis. 1984;43:8-17.
8. Wolfe F, Kleinheksel SM, Spitz PW, Lubeck DP, Fries JF, Young DY, et al. A multicenter study of hospitalization in rheumatoid arthritis: effect of health care system, severity, and regional difference. J Rheumatol. 1986;13: 277-84.
9. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med. 1980; 93:551-5.
10. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1985;13:841-5.
11. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl. 1996;44:13-22.
12. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol. 1995;34 Suppl 2:59-73.
13. Proudfit WL, Bruschke AV, Sones FM Jr. Natural history of obstructive coronary artery disease: ten-year study of 601 nonsurgical cases. Prog Cardiovasc Dis. 1978;21:53-78.
14. Kaplan HS. Hodgkin's Disease. Cambridge, MA: Harvard Univ Pr; 1972:372.
15. Mikkelsen WM, Dodge H. A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, Community Health Study. Arthritis Rheum. 1969;12:87-91.
16. O'Sullivan JB, Cathcart ES. The prevalence of rheumatoid arthritis. Followup evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med. 1972;76:573-7.
17. Corrigan AB, Robinson RG, Terenty TR, Dick Smith JB, Walters D. Benign rheumatoid arthritis of the aged. Br Med J. 1974;1:444-6.
18. Healey LA, Sheets PK. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol. 1988;15:750-2.
19. Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med. 1989;320:216-21.
20. Keat A, Thomas B, Dixey J, Osborn M, Sonnex C, Taylor-Robinson D. Chlamydia trachomatis and reactive arthritis: the missing link. Lancet. 1987; 1:72-4.
21. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol. 1993;20:2005-9.
22. Harrison BJ, Symmons DP, Brennan P, Bankhead CR, Barrett EM, Scott DG. et al. Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J Rheumatol. 1996;23:1326-31.
23. Pincus T, Callahan LF. How many types of patients meet classification criteria for rheumatoid arthritis? [Editorial] J Rheumatol. 1994;21:1385-9.
24. Emery P. Rheumatoid arthritis: not yet curable with early intensive therapy. Lancet. 1997;350:304-5.
25. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinica Trials. Arthritis Rheum. 1993;36:729-40.
26. van Riel PL. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis [Editorial]. Br J Rheumatol. 1994;31:793-4.
27. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994;41:86-9
28. Pincus T, Callahan LF. Prognostic markers of activity and damage in rheumatoid arthritis: why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease [Editorial]. Br J Rheumatol. 1995;34:196-9.
29. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis evidence that pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol. 1996; 35:1253-8.
30. Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective followup study of a Swedish cohort. Br J Rheumatol. 1996;35:1106-15.
31. Callahan LF, Pincus T, Huston JW 3d, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res. 1997; 10:381-94.
32. Hawley DJ, Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Res. 1992;5:130-5.
33. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-13
34. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997;15 Suppl 17: S27-38.
35. Bensen WG, Bensen W, Adachi JD, Tugwell P. Remodeling the pyramid: the therapeutic target of rheumatoid arthritis [Editorial]. J Rheumatol. 1990; 17:987-9.
36. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995;54:944-7.
37. O'Dell JR. Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal [Editorial]. Ann Rheum Dis. 1996;55:781-3.
38. Pincus T, Stein CM, Wolfe F. "No evidence of disease" in rheumatoid arthritis using methotrexate in combination with other drugs: a contemporary goal for rheumatology care? [Editorial] Clin Exp Rheumatol. 1997;15: S91-6.
39. Weinblatt ME. Rheumatoid arthritis: treat now, not later! [Editorial] Ann Intern Med. 1996;124:773-4.
40. O'Dell J. Combination DMARD therapy for rheumatoid arthritis: apparent universal acceptance [Abstract]. Arthritis Rheum. 1997;40:S50.
41. Wolfe F, Pincus T, Fries JF. Use of second line "disease modifying" anti-rheumatic drugs (DMARDs) within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under care of 142 US rheumatologists: an inception cohort study [Abstract]. US Inception Cohort Group. Arthritis Rheum. 1997;40:S218.
42. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol. 1998;37:612-9.
43. Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl. 1996;44:102-6.
44. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol. 1985; 12:245-52.
45. Mladenovic V, Domljan Z, Rozman B, Jaic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum. 1995;38:1595-603.
46. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott S, Morrell M, et al. Leflunomide plus methotrexate in refractory rheumatoid arthritis: a pilot study [Abstract] Arthritis Rheum. 1997;40:S193.
47. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptorfc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
48. Maini RN, Breedveld FC, Kalden JR, Smolen JS, David D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41: 1552-63.
49. Thould AK, Simon G. Assessment of radiological changes in the hands and feet in rheumatoid arthritis. Their correlation with prognosis. Ann Rheum Dis. 1966;25:220-8.
50. Brook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis. 1977;36:71-3.
51. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585-91.
52. Pincus T, Fuchs HA, Callahan LF, Nance EP Jr, Kaye JJ. Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis: a longitudinal analysis. J Rheumatol. 1998;25:636-40.
53. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990;17:994-1002.
54. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 1992;19:1885-94.
55. Fries JF. Clinical implications of the relative therapeutic toxicity of medications used to treatment rheumatoid arthritis. In: Wolfe F, Pincus T, eds. Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome, and Treatment. New York: Marcel Dekker; 1994:403-13.
56. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE. Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818-22.
57. Kremer JL, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29:822-31.
58. Kremer JM. Historical overview of the treatment of rheumatoid arthritis with an emphasis on methotrexate. J Rheumatol Suppl. 1996;44:34-7.
59. Weinblatt ME. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1998;34 Suppl:43-8.
60. Luukkainen R, Kajander A, Isomaki H. Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment. Scand J Rheumatol. 1977;6:189-92.
61. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036-8.
62. Rau R, Schattenkirchner M, Müller-Fassbender H, Kaik B, Zeidler H. A three year comparative multicenter study of auranofin (AF) and gold sodium thiomalate (GST) in the treatment of rheumatoid arthritis (RA). Clin Rheumatol. 1987;6 Suppl 2:43-52.
63. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized controlled trial. Ann Intern Med. 1996;124:699-707.
64. Forre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum. 1994;37:1506-12.
65. van Riel PL, van der Heijde DM, Nuver-Zwart IH, van de Putte LB. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J Rheumatol. 1995;22:1797-9.
66. Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum. 1996;39:1006-15.
67. Abu-Shakra M, Toker R, Flusser D, Flusser G, Friger M, Sukenik S, et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. Arthritis Rheum. 1998;41:1190-5.
68. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-7.
69. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol. 1993;32 Suppl. 1:28-37.
70. Csuka M, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. JAMA. 1986;255:2315-9.
71. McCarty DJ, Harman JG, Grassanovich JL, Qian C, Klein JP. Combination drug therapy of seropositive rheumatoid arthritis. J Rheumatol. 1995; 22:1636-45.
72. Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, et al. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol. 1994;21:2034-8.
73. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1992;35:259-69.
74. Willkens RF, Urowitz MB, Stablein DM, McKendry RJ Jr, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1992;35:849-56.
75. Faarvang KL, Egsmose C Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis. 1993;52:711-5.
76. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis - no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol. 1993;20: 645-9.
77. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36:1082-8.
78. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med. 1983;99:544-50.
79. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979;301:1410-2.
80. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol. 1988;41:1037-41.
81. Freireich EJ. The randomized clinical trial as an obstacle to clinical research. In: Varco RL, Delaney JP, eds. Controversy in Surgery. Philadelphia: WB Saunders; 1983:5-12.
82. Bombardier C Tugwell P. Controversies in the analysis of longterm clinical trials of slow acting drugs. J Rheumatol. 1985;12:403-5.
83. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol. 1991;18:1008-14.
84. Felson DT, Anderson JJ, Meenan RF. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum. 1990;33:140-9.
85. Pincus T. Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum. 1993;23(2 Suppl 1):2-10.
86. Pincus T, Stein CM. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? [Editorial] J Rheumatol. 1995;22:1611-7.
87. Tugwell P, Pincus T, Yocum D, Stein M, Gluck D, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137-41.
88. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxycnloroquine, or a combination of all three medications. N Engl J Med. 1996;334:1287-91
89. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine in early rheumatoid arthritis. Lancet. 1997;350:309-18.
90. O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol Suppl. 1996;44:72-4.
91. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1558-73.
92. Felson DT, Anderson JJ, Boers M, Bombardier C Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
93. Pincus T, Stein CM. ACR 20: clinical or statistical significance? Arthritis Rheum. 1999;42:1572-6.
94. Stein CM, Pincus T, Yocum D, Tugwell P, Wells G, Gluck O, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum. 1997;40:1843-51.
95. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
96. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, et al. Double-blind, placebo-controlled multicenter trial using chtmeric monoclonal anti-CD4 antibody, CM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 1995;38:1581-8.
97. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998;25:238-42.
98. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum. 1997;40:984-5.
99. Kremer JM. Methotrexate as a cornerstone for new therapeutic approaches. In: Kremer JM, ed. Rheumatic Disease Clinics of North America. Philadelphia: WB Saunders; 1998.
100. Kremer JM. Combination therapy with biologic agents in rheumatoid arthritis: perils and promise. Arthritis Rheum. 1998;41:1548-51.
101. Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol. 1984;3:11-20.
102. Pincus T. Documenting quality management in rheumatic disease: are patient questionnaires the best (and only) method? Arthritis Care Res. 1996; 9:339-48.
103. Strand V. The future use of biologic therapies in combination for the treatment of rheumatoid arthritis. J Rheumatol Suppl. 1996;44:91-6.
104. Koopman WJ, Moreland LW. Rheumatoid arthritis: anticytokine therapies on the horizon [Editorial]. Ann Intern Med. 1998;128:231-3.